Literature DB >> 16315442

What is a 'failure' of bisphosphonate therapy for osteoporosis?

John J Carey1.   

Abstract

Assessing the effectiveness of bisphosphonate therapy is problematic. Bone mineral density and markers of bone turnover are often used, but the true measure is prevention of new fractures.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16315442     DOI： 10.3949/ccjm.72.11.1033

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


  6 in total

1.  [Antiosteoporosis medication: useful monitoring, and how long should such treatment be continued?].

Authors:  W Demary
Journal:  Z Rheumatol       Date:  2006-09       Impact factor: 1.372

2.  Reciprocal regulation of adipocyte and osteoblast differentiation of mesenchymal stem cells by Eupatorium japonicum prevents bone loss and adiposity increase in osteoporotic rats.

Authors:  Min-Ji Kim; Woo-Seok Jang; In-Kyoung Lee; Jong-Keun Kim; Ki-Seung Seong; Cho-Rong Seo; No-Joon Song; Min-Hyuk Bang; Young Min Lee; Haeng Ran Kim; Ki-Moon Park; Kye Won Park
Journal:  J Med Food       Date:  2014-06-13       Impact factor: 2.786

3.  QCT bone mineral density responses to 1 year of oral bisphosphonate after total knee replacement for knee osteoarthritis.

Authors:  J K Lee; C H Lee; C H Choi
Journal:  Osteoporos Int       Date:  2012-02-23       Impact factor: 4.507

Review 4.  Bisphosphonate Related Osteonecrosis of the Jaw: An Update.

Authors:  Vijay Kumar; Raman Kant Sinha
Journal:  J Maxillofac Oral Surg       Date:  2013-08-09

5.  Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital.

Authors:  Kuntheavy Ing-Lorenzini; Jules Desmeules; Olivier Plachta; Domizio Suva; Pierre Dayer; Robin Peter
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

6.  Subgroup variations in bone mineral density response to zoledronic acid after hip fracture.

Authors:  Jay S Magaziner; Denise L Orwig; Kenneth W Lyles; Lars Nordsletten; Steven Boonen; Jonathan D Adachi; Chris Recknor; Cathleen S Colón-Emeric; Peter Mesenbrink; Christina Bucci-Rechtweg; Guoqin Su; Rasheeda Johnson; Carl F Pieper
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.